Lynx1 Capital Management LP - 10%+ Owner at TScan Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Company
Role
10%+ Owner
Stock Symbol
TCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
All Insider Reports
All Insider Reports

Lynx1 Capital Management LP - trading volume in the past year for TScan Therapeutics, Inc.

Holdings reported by Lynx1 Capital Management LP for TScan Therapeutics, Inc.

Class Num Shares Value Price $ Report Date Ownership Underlying Class Underlying Amount
Pre-funded Warrant (right to buy) 5,000,000 $35.6 M $7.13 Apr 19, 2024 Indirect Common Stock
Common stock, $0.0001 par value per share Common Stock 5,240,000 $13.2 M $2.51 May 31, 2023 Indirect
Common Stock 5,224,600 $13.1 M $2.51 May 31, 2023 Indirect
Common stock, $0.0001 par value per share 5,250,000 May 31, 2023 Indirect

Transactions reported by Lynx1 Capital Management LP for TScan Therapeutics, Inc.

Sym Class Transaction % Value $ Price $ Shares Shares After Date Ownership